Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (1): 12-16.doi: 10.6040/j.issn.1671-7554.0.2017.896
CHEN Bo, ZHANG Lei
CLC Number:
| [1] Killelea BK, Yang VQ, Mougalian S, et al. Neoadjuvant chemotherapy for breast cancer increases the rate of breast conservation: results from the National Cancer Database[J]. J Am Coil Surg, 2015, 220(6): 1063-1069. [2] King TA, Mowow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy[J]. Nat Rev Clin Oncol, 2015, 12(6): 335-343. [3] Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer[J]. N Engl J Med, 2012, 366(26): 2438-2441. [4] von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J]. J Clin Oncol, 2012, 30(15): 1796-1804. [5] Cortazar P, Zhang L, Untch M, et a1. Pathological complete response and long-term clinical benefit in breast cancer: the CT-NeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172. [6] Untch M, Konecny GE, Paepke S, et al. Current and future role of neoadjuvant therapy for breast cancer[J]. Breast, 2014, 23(5): 526-537. [7] Amiri-Kordestani L, Beaver JA, Cortazar P. Neoadjuvant therapy as a platform for drug development: current controversies and regulatory respectives[J]. Oncology(Williston Park), 2015, 29(11): 843-844. [8] DeMichele A, Yee D, Berry DA, et al. The neoadjuvant model is still the future for drug development in breast cancer[J]. Clin Cancer Res, 2015, 21(13): 2911-2915. [9] Sibylle L, Guatavo W, Valentina N, et al. Impact in delay of start of chemotherapy and surgery on PCR and survival in Breast cancer-a pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials[C]. 2017 ASCO,Abstract 571. https://www.asco.org/ [10] Anna W, Sami B, Kenneth H, et al. Effect of neoadjuvant chemotherapy regimen choice in breast cancer patients with pathologic complete response[C]. 2017 ASCO, Abstract 570. https://www.asco.org/ [11] Silverd P, Richardsona L, Eklunda C, et al. Efficacy of neoadjuvant eisplatin in triple-negative breast cancer[J]. J Clin Oncol, 2010, 28(7): 1145-1153. [12] Oakman C, Viale G, DiLeo A. Management of triple negative breast cancer[J]. Breast, 2010, 19(5): 312-321. [13] Dent R, Trudeau M, Pritehard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15Pt1): 4429-4434. [14] Von MG, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatinin patients with triple-negative and Her-2-positive early breast cancer(GeparSixto; GBG 66): a randomised phase 2 trial[2]. Lancet Oncol, 2014, 15(7): 747-756. [15] Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and /or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603(Alliance)[J]. J Clin Oncol, 2015, 33(1): 13-21. [16] Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparib-carboplatin treatment in breast cancer[J]. N Engl J Med, 2016, 375(1): 23-34. [17] Daniel E, Nathaly PN, Hugo AF, et al. Improving pathological responses in locally advanced triple negative breast cancer comparison between CbD and AT-T regimens[C]. 2017 ASCO,Abstract 585. https://www.asco.org/ [18] Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy[J]. N Engl J Med, 2017, 76(22): 2147-2159. doi: 10.1056/NEJMoa1612645. [19] von Minckwitz G, Blohmer JU, Costa SD, et al. Response-guided neoadjuvant chemotherapy for breast cancer[J]. J Clin Oncol, 2013, 31(29): 3623-3630. doi: 10.1200/JCO.2012.45.0940. [20] Hee JK, Woo CN, Eun Sook L, et al. A phase III, open label, prospective, randomized, multicenter, neoadjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, breast cancer(KBCSG 012)[C]. 2017 ASCO, NEST Trial. https://www.asco.org/ [21] Gianni L, Pienkowski T, Im YH, et al. 5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-pOSitive breast cancer(Neosphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800. [22] Jens H, Eileen H, JOSe B, et al. Survival outcomes of the neoaltto study: updated results of a randomized multicenter phase 3 neoadjuvant trial[C]. 2017 ASCO,Abstract 512. https://www.asco.org/ [23] van Ramshorst MS, van Werkhoven E, Mandjes IA, et al. A phase III trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-pOSitive breast cancer: the TRAIN-2 study(BOOG 2012-03)[C]. 2017 ASCO,Abstract 507. https://www.asco.org/ [24] Justin S, Yauheni VB, Valery B, et al. Double-blind, randomized phase 3 study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate, versus reference trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer[C]. 2017 ASCO,Abstract 510. https://www.asco.org/ [25] Rita N, Minetta C, Liu, et al. Pembrolizum ab plus standard neoadjuvant therapy for high-risk breast cancer: Result from the I-SPY 2 Trial[C]. 2017 ASCO,I-SPY 2 Trial. https://www.asco.org/ |
| [1] | RUAN Xiangyan, CHENG Jiaojiao, DU Juan, GU Muqing. Ovarian tissue cryopreservation and preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 24-30. |
| [2] | LIN Yun, XIE Yanqiu. Fertility protection and preservation in breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 42-46. |
| [3] | HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43. |
| [4] | Qifeng YANG,Ning ZHANG. Sentinel lymph node biopsy of breast cancer in the era of precision medicine [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 1-5. |
| [5] | QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82. |
| [6] | WANG Fuli, SUN Yinping, QIN Jie, RONG Jiansheng. Efficacy of DC-CIK cells combined with EGFR-TKI for 35 elderly patients with advanced EGFR-mutant lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 110-117. |
| [7] | ZHAO Tingting, QI Yana, ZHANG Ying, YUAN Bing, HAN Mingyong. Mouse breast cancer induces changes of the microenvironment in pre-metastatic lung tissue [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 24-29. |
| [8] | Zhuxiu CHU,Wenjing ZHAO,Xiaoyan LI,Xiaoli KONG,Tingting MA,Liyu JIANG,Qifeng YANG. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139. |
| [9] | WANG Zhe, LIU Yujie, MAO Qian, GUAN Peixia, BAO Qihan, LI Chengsheng, QIAO Xiaowei, PAN Qingzhong, WANG Suzhen. Evaluation of the efficacy of different regimens for early triple negative breast cancer based on the inverse probability of treatment weighting method [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 113-118. |
| [10] | LI Wanwan, ZHOU Wenkai, DONG Shuqing, HE Shiqing, LIU Zhao, ZHANG Jiaxin, LIU Bin. Construct of a risk assessment model of breast cancer immune-related lncRNAs based on the database information [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 74-84. |
| [11] | KONG Xue, LI Juan, DUAN Weili, SHI Shuang, LI Peilong, DU Lutao, MAO Haiting, WANG Chuanxin. Effects of lncRNA AC012073.1 on the migration and invasion of human breast cancer cells and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 70-78. |
| [12] | GENG Ling, ZHANG Huanhuan, ZHANG Tiantian. Analysis of dietary protein intake of 459 elderly women during in vitro fertilization [J]. Journal of Shandong University (Health Sciences), 2021, 59(11): 29-34. |
| [13] | YOU Xueting, TIAN Xingsong. Analysis of clinicopathological characteristics of 3 514 cases of breast cancer over 9 years [J]. Journal of Shandong University (Health Sciences), 2021, 59(1): 49-54. |
| [14] | Chuanzhu YAN,Wei WANG,Kunqian JI,Yuying ZHAO. Mitochondrial dysfunction and related brain diseases [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 34-41. |
| [15] | Anjing CHEN,Xun ZHANG. The new strategies of targeting SUMOylation in the treatment of glioma [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 88-94. |
|
||
